Rights offerings

Samsung Biologics dilutes holders 4.9% to buy its way into GLP-1 peptides

Samsung Biologics is paying for peptide capacity with new stock rather than debt, and the arithmetic inside its own 15.4 trillion won decade plan says the antibody campus, not GLP-1, still gets most of the money.